XDR TB in South Africa - What lies ahead?

South African Family Practice

Volumn 48, Issue 10, 2006, Pages 58-59

  Thaver, Veneesha ^a   Ogunbanjo, G A ^a  

^a SEFAKO MAKGATHO HEALTH SCIENCES UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; CAPREMYCIN; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; SPARFLOXACIN; UNCLASSIFIED DRUG; VIOMYCIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE ASSOCIATION; DRUG COST; DRUG RESEARCH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; PUBLIC HEALTH SERVICE; SHORT SURVEY; SOUTH AFRICA;

EID: 33847049419     PISSN: 20786190     EISSN: 20786204     Source Type: Journal    
DOI: 10.1080/20786204.2006.10873489     Document Type: Short Survey

References (16)

1. De Cock K. The new tuberculosis. Afr Health 1994; 16(3):8-10.
2. Lademarco MF, Castro KG. Epidemiology of tuberculosis. Semin Respir Infect 2003; 18 (4):225-40.
3. Harries AD. Tuberculosis in Africa; Clinical presentation and management. Pharmacol Ther 1996; 73 (1): 1-50.
4. Flynn JL, Ernst JD. Immune responses in tuberculosis. Curr Opin Immun 2000; 4(12): 432-436.
5. Skenders G, Fry AM, ProKopovica I. Multidrug-resistant tuberculosis detection. Latvia. Emerg Infect Dis 2005; 11(9): 1461-3.
6. Petrini B, Hoffner S. Drug-resistant and multidrug-resistant tubercle bacilli. Int J Antimicrob Ag 1999; 13:93-7.
7. No authors listed. XDR TB- a global threat. Lancet 2006; 368 (9540): 964.
8. World Health Organization Report 2002. www.who.int/gtb/publications/ globrep99/download.html (accessed 21 November 2006)
9. Tattevin P, Chapplain JM, Lesprit P, Billy C, Roblot F, Alfandari S, Bernard L, Rouveix E, Bouvet E. Tuberculosis treatment duration in France: From guidelines to daily practice. Eur J Int Med 2006; 17: 427-429.
10. Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second line drugs-worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006 Mar 24; 55(11): 301-5.
11. NJMS National Tuberculosis Center. Brief History of Tuberculosis (revised July 23, 1996). www.umdnj.edu/ ~ntbcweb/history.htm (accessed 21 November 2006)
12. Espinol MA, Reingold AI, Koenig E. TB and HIV testing could be combined Nurs Times 1995; 91(17): 10.
13. National Center for HIV, STD and TB Prevention. Extensively Drug-Resistant Tuberculosis (XDR TB) Update. www.cdc.gov/nchstp/tb/xdrtbupdate. htm (accessed 21 November 2006)
14. Masjedi MR, Farnia P, Sorooch S, et al. Extensively drug resistant tuberculosis: 2 years of surveillance in Iran. Clin Infect Dis 2006; 43(7): 841-7.
15. National Department of Health, South Africa. The Global Plan to Stop TB, 2006-2015 revised Reflect the threat of XDR-TB. www.doh.gov.za/docs/xdr.pdf (accessed 22 November 2006)
16. South African National Health Act 61 of 2003. www.info.gov.za/gazette/ acts/2003/a61-03.pdf (accessed 21 November 2006)